, Tracking Stock Market Picks
Enter Symbol:
Dendreon Corporation (DNDN) [hlAlert]

up 4,509.09 %

Dendreon Corporation (DNDN) rated Sell with price target $4 by UBS

Posted on: Friday,  Mar 14, 2008  9:25 AM ET by UBS

UBS rated Sell Dendreon Corporation (NASDAQ: DNDN) on 03/14/2008, when the stock price was $5.07. Since
then, Dendreon Corporation has lost 97.83% as of 11/14/2014's recent price of $0.11.
If you would have followed this UBS's recommendation on DNDN, you would have gained 4509.09% of your investment in 2436 days.

Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. Through the use of antigen engineering and proprietary cell separation technologies, Dendreon develops therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer. In addition to its products for cancer, Dendreon also intends to pursue the application of its technologies in the fields of autoimmune diseases, allergies and infectious diseases.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/14/2008 9:25 AM Sell
5.07 4.00
as of 12/24/2008
1 Week down  -11.61 %
1 Month down  -369.15 %
3 Months down  -464.04 %
1 YTD down  -338.42 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy